CASI Pharmaceuticals Appoints James Huang to Board of Directors
CASI Pharmaceuticals (NASDAQ:CASI) has appointed James Huang as an Independent Director to its Board, effective October 1, 2025. Huang brings over 35 years of biotech experience as Founder and Managing Partner of Panacea Venture, and former Managing Partner at Kleiner Perkins China and Vivo Ventures.
The appointment strengthens CASI's leadership as it focuses on developing CID-103, its anti-CD38 monoclonal antibody program for autoimmune diseases and organ transplant rejection. Notably, Panacea Venture, a current CASI shareholder, plans to acquire up to 1.5 million newly issued shares of CASI common stock in a registered transaction.
CASI Pharmaceuticals (NASDAQ:CASI) ha nominato James Huang come Consigliere indipendente del Consiglio di Amministrazione, con effetto dal 1 ottobre 2025. Huang porta oltre 35 anni di esperienza nel biotech come Fondatore e Managing Partner di Panacea Venture e come ex Managing Partner presso Kleiner Perkins China e Vivo Ventures.
La nomina rafforza la leadership di CASI mentre l’azienda si concentra sullo sviluppo di CID-103, il suo programma di anticorpo monoclonale anti-CD38 per malattie autoimmuni e rigetto di organi trapiantati. Da notare che Panacea Venture, attuale azionista di CASI, intende acquisire fino a 1,5 milioni di nuove azioni emesse di azioni ordinarie CASI in una transazione registrata.
CASI Pharmaceuticals (NASDAQ:CASI) ha nombrado a James Huang como Director Independiente de su Junta Directiva, con efectos a partir del 1 de octubre de 2025. Huang aporta más de 35 años de experiencia en biotecnología como Fundador y Managing Partner de Panacea Venture, y fue Managing Partner en Kleiner Perkins China y Vivo Ventures.
El nombramiento fortalece el liderazgo de CASI mientras se centra en desarrollar CID-103, su programa de anticuerpo monoclonal anti-CD38 para enfermedades autoinmunes y el rechazo de trasplantes de órganos. Cabe destacar que Panacea Venture, accionista actual de CASI, planea adquirir hasta 1,5 millones de nuevas acciones emitidas de acciones ordinarias de CASI en una operación registrada.
CASI Pharmaceuticals (NASDAQ:CASI)가 James Huang을 이사회 독립 이사로 임명했습니다. 임명은 2025년 10월 1일부터 효력을 발휘합니다. Huang은 Panacea Venture의 창립자이자 Managing Partner로서 35년이 넘는 생명공학 분야 경력을 가지고 있으며, Kleiner Perkins China와 Vivo Ventures의 전 managing partner였습니다.
이번 임명은 CASI가 면역질환과 장기 이식 거부 반응에 대한 항-CD38 단클론항체 CID-103 개발에 집중하는 가운데 리더십을 강화합니다. 특히 현재 CASI 주주인 Panacea Venture는 등록 거래를 통해 최대 150만 주의 신규 발행 주식을 CASI 보통주로 매입할 계획입니다.
CASI Pharmaceuticals (NASDAQ:CASI) a nommé James Huang conseiller indépendant de son conseil d’administration, à effet le 1er octobre 2025. Huang apporte plus de 35 ans d’expérience dans le biotechnologique en tant que fondateur et managing partner de Panacea Venture, et a été Managing Partner chez Kleiner Perkins China et Vivo Ventures.
Cette nomination renforce le leadership de CASI alors que l’entreprise se concentre sur le développement de CID-103, son programme d’anticorps monoclonaux anti-CD38 pour les maladies auto-immunes et le rejet d’organes transplantés. À noter que Panacea Venture, actuel actionnaire de CASI, prévoit d’acquérir jusqu’à 1,5 million d’actions ordinaires CASI nouvellement émis dans une transaction enregistrée.
CASI Pharmaceuticals (NASDAQ:CASI) hat James Huang zum unabhängigen Direktor des Vorstands ernannt, wirksam ab dem 1. Oktober 2025. Huang verfügt über mehr als 35 Jahre Biotech-Erfahrung als Gründer und Managing Partner von Panacea Venture und war früher Managing Partner bei Kleiner Perkins China und Vivo Ventures.
Diese Ernennung stärkt die Führung von CASI, während sich das Unternehmen auf die Entwicklung von CID-103, sein Programm für ein anti-CD38-Molekular-Antikörper gegen Autoimmunerkrankungen und Transplantatabstoßung, konzentriert. Bemerkenswert ist, dass Panacea Venture, ein aktueller CASI-Aktionär, plant, in einer registrierten Transaktion bis zu 1,5 Millionen neu ausgegebene CASI-Stammaktien zu erwerben.
CASI Pharmaceuticals (NASDAQ:CASI) قد عيّنت James Huang كعضو مستقل في مجلس الإدارة، اعتباراً من 1 أكتوبر 2025. يجلب Huang أكثر من 35 عاماً من الخبرة في التكنولوجيا الحيوية كمؤسّس وشريك إداري في Panacea Venture، وكونه Managing Partner سابقاً في Kleiner Perkins China وVivo Ventures.
تعزز هذه التعيينة قياديّة CASI بينما تركّز على تطوير CID-103، برنامجها من الغلوبين المناعي المضاد-CD38 للأمراض المناعية الذاتية ورفض الزراعة للعضو المزروع. ومن الجدير بالذكر أن Panacea Venture، وهي مساهم حالياً في CASI، تخطط لشراء حتى 1.5 مليون سهم عادي جديد مُصدر من CASI في صفقة مُسجّلة.
CASI Pharmaceuticals (NASDAQ:CASI) 已任命 James Huang 为独立董事，任命自 2025 年 10 月 1 日起生效。Huang 具备 超过 35 年的生物技术经验，曾任 Panacea Venture 的创始人兼管理合伙人，亦曾任 Kleiner Perkins China 与 Vivo Ventures 的 管理合伙人。
此次任命在 CASI 专注于开发 CID-103——其用于自身免疫性疾病和器官移植排斥的抗 CD38 单克隆抗体计划——的同时，进一步巩固其领导地位。值得注意的是，当前 CASI 的股东 Panacea Venture 计划在一项注册交易中购买 多达 150 万股新发行的 CASI 普通股。
- Appointment of highly experienced board member with 35+ years of biotech expertise
- Strategic investment commitment from Panacea Venture for 1.5M new shares
- Enhanced leadership for CID-103 development program with global expansion experience
- Potential share dilution from new 1.5M share issuance
- Industry veteran brings over 35 years of biotech experience as a successful entrepreneur and investor
- Operating experience to significantly enhance development program of CID-103 (anti-CD38 mAb)
SOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 26, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced the appointment of James Huang as an Independent Director to the CASI Board of Directors, effective as of October 1, 2025.
Mr. Huang brings over 35 years of experience building and investing in biopharma companies globally. As Founder and Managing Partner of Panacea Venture, and previously Managing Partner at Kleiner Perkins (KPCB) China and Vivo Ventures, he has guided numerous cross-border companies through critical stages of growth, financing, and global expansion. Earlier in his career, he held senior roles in business development, sales & marketing, and research & development at Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Myers Squibb and ALZA Corp. (acquired by Johnson & Johnson). Mr. Huang serves as a member of the board of directors of Kindstar Globalgene Technology, Inc., Connect Biopharma Holdings Limited, Lee's Pharmaceutical Holdings Limited, Atara Biotherapeutics, Inc., and several private companies. He received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.
"I am honored to join the CASI Board as the company embarks on a pivotal new chapter with a sharpened U.S. focus and a commitment to rapidly advance clinical development of CID-103 in autoimmune diseases and antibody-mediated rejection in solid organ transplants," said Mr. Huang. "I look forward to partnering with company leadership to bring strategic perspective, principled governance, and long-term alignment with shareholders as CASI establishes itself as a U.S.-centric clinical-stage leader in autoimmune and transplant medicine."
David Cory, CEO of CASI, added, "As our CID-103 anti-CD38 program progresses in the clinic and delivers data across diverse patient populations and indications, we expect James' global perspective and proven ability to scale companies will be invaluable. I am very pleased to welcome James to our Board and look forward to working closely with him as we drive CASI toward its next phase of growth."
Panacea Venture is a current CASI Pharmaceuticals shareholder and, in connection with Mr. Huang's appointment to the Board, plans to acquire up to approximately 1.5 million newly issued shares of CASI Pharmaceuticals common stock from CASI in a registered transaction.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a publicly-traded, biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.
CID-103 is a fully human IgG1, potentially best-in-class, clinical stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated an encouraging pre-clinical efficacy and clinical safety profile compared to other anti-CD38 monoclonal antibodies, and for which CASI owns exclusive global rights. CASI is actively recruiting and dosing patients in a Phase 1 / 2 study in immune thrombocytopenic purpura (ITP). In parallel, CASI recently received FDA IND clearance to conduct a Phase 1/2 study in renal allograft antibody-mediated rejection (AMR) with plans for first patient in Q1 2026.
Pursuant to a May 2025 announcement that CASI had entered into an equity and asset transfer agreement with Kaixin Pharmaceuticals to divest CASI China business, the company plans to complete divestiture in Q2 2026.
More information on CASI is available at www.casipharmaceuticals.com.
Forward Looking Statements
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the business outlook and quotations from management in this announcement, as well as the Company's strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: uncertainties related to the possibility that the transaction for the divestiture of certain assets in China (the "Transaction") will not occur as planned if events arise that result in the termination of the Equity and Assets Transfer Agreement, or if one or more of the various closing conditions to the Transaction are not satisfied or waived; the possibility that our plan with respect to our business operations after the consummation of the Transaction can be implemented successfully; our recurring operating losses have raised substantial doubt regarding our ability to continue as a going concern; the possibility that we may be delisted from trading on The Nasdaq Capital Market if we fail to satisfy applicable continued listing standards; the volatility in the market price of our ordinary shares; the risk of substantial dilution of existing shareholders in future share issuances; the difficulty of executing our business strategy on a global basis including China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; legal or regulatory developments in China that adversely affect our ability to operate in China; our lack of experience in manufacturing products and uncertainty about our resources and capabilities to do so on a clinical or commercial scale; risks relating to the commercialization, if any, of our products and proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); our inability to predict when or if our product candidates will be approved for marketing by the U.S. Food and Drug Administration, European Medicines Agency, PRC National Medical Products Administration, or other regulatory authorities; our inability to receive approval for renewal of license of our existing products; the risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the risks associated with our product candidates, and the risks associated with our other early-stage products under development; the risk that result in preclinical and clinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; our ability to protect our intellectual property rights; the lack of success in the clinical development of any of our products; and our dependence on third parties; the risks related to our dependence on Juventas to conduct the clinical development of CNCT19 and to partner with us to co-market CNCT19; risks related to our dependence on Juventas to ensure the patent protection and prosecution for CNCT19; the risk related to the Company's ongoing development of and regulatory application for CID-103 with respect to the treatment of antibody-mediated rejection for organ transplant and the license arrangements of CID-103; risks relating to interests of our largest shareholder and our Chairman that differ from our other shareholders; risks related to the development of a new manufacturing facility by CASI Pharmaceuticals (Wuxi) Co., Ltd. and risks related to our disagreement with Acrotech with respect to the termination of agreements regarding EVOMELA®. Further information regarding these and other risks is included in the Company's filings with the SEC. All information provided herein is as of the date of this announcement, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. We caution readers not to place undue reliance on any forward-looking statements contained herein.
EVOMELA® is proprietary to Acrotech Biopharma Inc. and its affiliates. FOLOTYN® is proprietary to Acrotech Biopharma Inc and its affiliates. The Company is currently involved in disputes and legal proceedings related to certain pipeline products, including EVOMELA® and CNCT-19. Please refer to the Company's earlier SEC filing for further information.
COMPANY CONTACT:
Ingrid Choong, PhD
650-619-6115
ingridc@casipharmaceuticals.com
SOURCE: CASI Pharmaceuticals
View the original press release on ACCESS Newswire
FAQ
Who is James Huang and what is his role at CASI Pharmaceuticals (NASDAQ:CASI)?
What is CASI Pharmaceuticals' main development focus?
How many shares will Panacea Venture acquire from CASI Pharmaceuticals?
What is James Huang's background in the biotech industry?
